Compare MIR & RLAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MIR | RLAY |
|---|---|---|
| Founded | 2005 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 4.1B |
| IPO Year | 2020 | 2020 |
| Metric | MIR | RLAY |
|---|---|---|
| Price | $16.66 | $19.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | ★ $27.25 | $19.50 |
| AVG Volume (30 Days) | ★ 3.3M | 2.8M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 161.11 | 31.78 |
| EPS | ★ 0.02 | N/A |
| Revenue | N/A | ★ $15,355,000.00 |
| Revenue This Year | $23.95 | N/A |
| Revenue Next Year | $7.32 | $324.03 |
| P/E Ratio | $810.50 | ★ N/A |
| Revenue Growth | N/A | ★ 53.44 |
| 52 Week Low | $14.11 | $4.32 |
| 52 Week High | $30.28 | $21.27 |
| Indicator | MIR | RLAY |
|---|---|---|
| Relative Strength Index (RSI) | 53.89 | 42.46 |
| Support Level | $15.52 | $18.03 |
| Resistance Level | $17.48 | $20.82 |
| Average True Range (ATR) | 0.63 | 0.69 |
| MACD | 0.04 | -0.06 |
| Stochastic Oscillator | 47.98 | 20.12 |
Mirion Technologies Inc provides products, services, and software that allow customers to safely leverage the power of ionizing radiation for applications that benefit the health, safety, vitality, and technological progress of the human experience. The Company manages its operations through two segments: Nuclear & Safety and Medical. The Medical segment improves the quality and safety of cancer care delivery and supports applications across medical diagnostics and practitioner safety. The Nuclear & Safety segment powers advancements in nuclear energy and critical radiation safety, measurement and analysis applications across laboratories, research and other industrial markets such as defense.
Relay Therapeutics Inc is a clinical-stage precision medicine company transforming the drug discovery process and bringing life-changing therapies to patients. The Dynamo platform of the company integrates an array of leading-edge computational and experimental approaches designed to drug-protein targets that have previously been intractable or inadequately addressed. The company is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including product candidates, RLY-8186, RLY-2608, RLY-4008 and others.